Cytokinetics, Inc. (CYTK)

[H2R]

New SOS Article on CYTK

https://smithonstocks.com/cytokinetics-a-look-at-the-clinical-trial-programs-underway-cytk-buy-13-00/

Here is a snippet:

I consider Cytokinetics as having arguably the best pipeline potential of any emerging biotechnology company (roughly defined as having a market capitalization under $2 billion and with no commercial products). It has three distinct drugs with exciting potential in late stage development.

In partnership with Amgen, omecamtiv mecarbil is being studied in a massive 8000 plus patient phase 3 trial.
Cytokinetics is conducting a phase 3 trial of tirasemtiv in ALS without a partner.
In partnership with Astellas, they are developing CK-107 in phase 2 trials in four indications-spinal muscular atrophy, COPD, elderly patients with limited mobility, and ALS.
Importantly, CYTK is well financed. It currently has about $264 million of cash which management indicates will carry the Company through 24 months of operations. Potential milestone payments could add to financial reserves.